국가: 말레이시아
언어: 영어
출처: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Lorlatinib
PFIZER (MALAYSIA) SDN. BHD.
Lorlatinib
30 Tablets; 90 Tablets; 120 Tablets; 60 Tablets
Pfizer Manufacturing Deutschland GmbH.
Pfizer Confidential _CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_ LORVIQUA ® FILM COATED TABLET Lorla tinib (25 mg and 100 mg) PLD Title : Lorlatinib (LORVIQUA ® ) PLD Date : 122060 MayJanuaryAugustAugust 202210 Country : Malaysia Reference Document : 25 mg and 100 mg LORVIQUA Film-coated tablet Malaysia CLD dated 1010243 MayJanuaryuneJuly 202210 Reason for change : New PLD creation : PfLEET Number 2021-0068787 (S1): - To update PLD as per effective Malaysia CLD dated 23 June 20212020-0058803 (D) - To update as per BOH recommendation and update according to new template : PfLEET Number 2019-0057286 (D): line extension for 1 st line indicationTo amend serial number : PfLEET 2022-00783312022-0075271 (M) : To align indication as per CDSEU SPC. : To add serial number : PfLEET 2020-0060746 (D)- To incorporate BOH suggestion : PfLEET 2020-0062523 (S1)- To update PLD as per BOH request : PfLEET 2020-0063658 (S2)- To update PLD as per BOH request dated 18 August 2020 FORMATTED: Hidden FORMATTED: Hidden FORMATTED: Superscript, Hidden COMMENTED [SN1]: Please consider to superscript all the ordinals given throughout the document. FORMATTED: Hidden COMMENTED [GP2R1]: Revised FORMATTED: Hidden FORMATTED: Font: (Default) Times New Roman, 10 pt FORMATTED: Hidden FORMATTED: Hidden FORMATTED: Hidden Pfizer Confidential _CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_ LORVIQUA ® FILM COATED TABLET Lorlatinib (25 mg and 100 mg) 1 FORMATTED: Font: Not Bold WHAT IS IN THIS LEAFLET 1. What LORVIQUA is used for 2. How LORVIQUA works 3. Before you use LORVIQUA 4. How to use LORVIQUA 5. While you are using it 6. Side Eeffects 7. Storage and Disposal of LORVIQUA 8. Product Description 9. Manufacturer and Product Registration Holder 10. Date of Revision 11. Serial Number WHAT LORVIQUA IS USED FOR LORVIQUA is used to treat adults with metastatic lung cancer called advanced non-small cell lung cancer (NSCLC) whose tumors are caused by a gene defect called anaplastic lymphoma kinase (ALK). LORVIQUA can be prescribed if you have not be 전체 문서 읽기
PFIZER LORVIQUA ® 1. NAME OF THE MEDICINAL PRODUCT LORVIQUA 25 MG FILM COATED TABLETS LORVIQUA 100 MG FILM COATED TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 25 mg film-coated tablet contains 25 mg of lorlatinib. Each 100 mg film-coated tablet contains 100 mg of lorlatinib. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet 25 mg: 8 mm round tan immediate release film-coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side. 100 mg: oval (8.5 × 17 mm) lavender immediate release film-coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS LORVIQUA as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. LORVIQUA as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC whose disease has progressed after: • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or • crizotinib and at least one other ALK TKI 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with lorlatinib should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. ALK testing Detection of ALK positive NSCLC is necessary for selection of patients for treatment with lorlatinib because these are the only patients for whom benefit has been shown. Assessment for ALK positive NSCLC should be performed by laboratories with 1 demonstrated proficiency in the specific technology being utilized. Improper assay performance can lead to unreliable test results. Recommended dosing The recommended dose schedule of LORVIQUA is 100 mg taken orally once daily continuously. Continue treatment as long as the patient is deriving clinical benefit from therapy. LORVIQUA may be taken with or without food (see Section 5.2). Patients sh 전체 문서 읽기